Preliminary data from several multiple sclerosis patients who underwent CCSVI treatment shows that the treatment was safe, reduced disease symptoms and improved quality of life.
The results of CCSVI treatment on 125 patients will need to be supported with future controlled, randomized, blinded trials that evaluate surgical and endovascular options, said Dr. Manish Mehta, of the Albany (N.Y.) Medical College, at the Vascular Annual Meeting.
This follows Dr. Paolo Zamboni’s identification in 2009 of stenosis in the internal jugular veins and azygous vein of patients with MS (J. Neurol. Neurosurg. Psychiatry 2009;80:392-9), which he referred to as chronic cerebro-spinal venous insufficiency, or CCSVI.
“Dr. Zamboni’s theory has been that stasis of blood can cause reflux, and reflux can cause propagation and [can] break down the blood-brain barrier,” said Dr. Mehta. As a result micro bleeds can let red blood cells escape into the brain matter, leading to hemosiderin deposits that can become the inflammatory facilitation necessary for an autoimmune response, he added.
It is unclear if the relationship between CCSVI and MS is causative, or if CCSVI could play a role in the etiology of the disease.
In 2009, Dr. Zamboni described 65 patients who had significant improvements in functional composite scores and quality of life one year after CCSVI treatment. (J. Vasc. Surg. 2009;50;1348-58.e1-3).
This preliminary data that Dr. Mehta presented at the meeting was from the LIBERATION study, which was created to assess the use of balloon angioplasty for people with CCSVI and MS. It is a prospective, double-blind, randomized study that is enrolling 600 patients.
Angeles hospital in Mexico provides high quality CCSVI treatment and has a great success rate. For further information on what we offer please contact us using the form on the right.